Validation of a 12‐color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection

This is the authors' abstract. We don't add key points for this paper.

The validation met all criteria and obtained FDA IDE (investigational device exemption) approval. This study provides ample technical and professional details in setting up the AML MRD flow cytometry assay and illustrates through the example of the "fit for purpose" validation process. We also highlight the need for further characterization of abnormal blasts bearing the potential for AML relapse.